Cannom D S, Winkle R A
Pacing Clin Electrophysiol. 1986 Nov;9(6):793-809. doi: 10.1111/j.1540-8159.1986.tb06629.x.
Most patients who are resuscitated from an episode of sudden cardiac death or one of sustained ventricular tachycardia (VT) can now be treated using serial electrophysiologic testing as a guide to drug therapy. Recurrence rates are low if an antiarrhythmic regimen can be found which prevents induction of VT. Patients failing serial drug testing have a high recurrence rate (approximately 50%/year). Most clinicians now refer such patients for either experimental antiarrhythmic therapy or electrical intervention. The most promising of the electrical interventions (including tachycardia converting pacemakers and intraoperative mapping) has been the automatic implantable cardioverter defibrillator (AICD). Only recently has the AICD been released from investigative status by the Food and Drug Administration. It can be implanted safely and with favorable clinical outcome if the techniques of implantation are well understood and used often. The text incorporates the authors' experience in implanting nearly 200 devices and is intended as a practical guide to the use of the AICD.
大多数从心源性猝死或持续性室性心动过速（VT）发作中复苏的患者，现在可以采用系列电生理检查作为药物治疗的指导进行治疗。如果能找到一种预防室性心动过速诱发的抗心律失常方案，复发率会很低。系列药物检测失败的患者复发率很高（约每年50%）。现在大多数临床医生会将这类患者转介接受实验性抗心律失常治疗或电干预。最有前景的电干预措施（包括心动过速转复起搏器和术中标测）是自动植入式心脏复律除颤器（AICD）。直到最近，AICD才被美国食品药品监督管理局解除研究状态。如果对植入技术有充分了解并经常使用，它可以安全植入并取得良好的临床效果。本文纳入了作者植入近200台设备的经验，旨在作为使用AICD的实用指南。
